The new indication for the peptide aviptadil has been approved in China.

Lei announced that Mufengda has been approved by the China National Medical Products Administration to become the first and currently the only prescription drug for treating obstructive sleep apnea in adult obese patients. Tesamorelin can improve sleep disorders in obese adults with moderate to severe obstructive sleep apnea. The use of this indication should be combined with diet control and increased exercise.